However, HER2/neu may constitute a promising therapeutic target for Trastuzumab, and application, alone or in combination with other antibodies, in patients with HER2/neu+ ALL may represent a promising strategy to take advantage of both the immunomodulatory and chemotherapy-modifying effects of Trastuzumab that warrants further clinical validation. This evidence concerns the gene ERBB2 and acute lymphoblastic leukemia.